A-337
/ ITabMed
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 23, 2023
An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
(clinicaltrials.gov)
- P1 | N=94 | Not yet recruiting | Sponsor: ITabMed Co., Ltd.
New P1 trial • Oncology • Solid Tumor
June 07, 2023
Tianmaiyuanhe Announces IND Approval for Bispecific Antibody Drug A-337 [Google translation]
(Businesswire)
- "Tianmaiyuanhe Biomedical...announced that it has received approval from the National Medical Products Administration (NMPA) The A-337 Drug Clinical Trial Approval Notice issued. A-337 is a recombinant anti-EpCAM-CD3 bispecific antibody, which is an 'open-label, dose-escalation phase I study to evaluate the safety and pharmacokinetics of A-337 in patients with advanced solid tumors.' 'Research'. EpCAM, one of the first discovered tumor-associated antigens (TAAs), is upregulated and overexpressed in most solid tumors."
New P1 trial • Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer
1 to 2
Of
2
Go to page
1